Preliminary results from the RADIANT trial were recently presented and suggest that adjuvant erlotinib may prolong disease-free survival (DFS) in patients with EGFR mutation-positive NSCLC, but adjuvant erlotinib did not significantly improve DFS over placebo in the overall patient population 69,70. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.